Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT03631199
What this trial is testing

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 673
Early research (Phase 1)Active Not RecruitingNCT04676477
What this trial is testing

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 246
Not applicableStudy completedNCT01153399
What this trial is testing

A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 589
Large-scale testing (Phase 3)UnknownNCT00022009
What this trial is testing

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
The Christie NHS Foundation Trust
Testing effectiveness (Phase 2)UnknownNCT00908336
What this trial is testing

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Who this might be right for
Non-Small Cell Lung Cancer
Hospital Arnau de Vilanova 70
Testing effectiveness (Phase 2)Study completedNCT00356122
What this trial is testing

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Sanofi 53
Testing effectiveness (Phase 2)Study completedNCT00550173
What this trial is testing

Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Eli Lilly and Company 247
Not applicableStudy completedNCT03911219
What this trial is testing

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

Who this might be right for
Stage IV Non-small Cell Lung CancerExtensive-stage Small Cell Lung CancerAdvanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC
iOMEDICO AG 154
Large-scale testing (Phase 3)Looking for participantsNCT05989542
What this trial is testing

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Who this might be right for
Non-small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 136
Testing effectiveness (Phase 2)Looking for participantsNCT07697586
What this trial is testing

SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 206
Early research (Phase 1)Looking for participantsNCT07589205
What this trial is testing

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Who this might be right for
Solid TumorColorectal CancerNon-small Cell Lung Cancer+2 more
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 493
Not applicableStudy completedNCT03037086
What this trial is testing

Asia PDL1 Study Among NSCLC Patients

Who this might be right for
Locally Advanced or Metastatic NSCLC
AstraZeneca 658
Post-approval studies (Phase 4)Study completedNCT05219162
What this trial is testing

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Who this might be right for
Advanced NSCLC
AstraZeneca 182
Testing effectiveness (Phase 2)Looking for participantsNCT05732831
What this trial is testing

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Who this might be right for
Locally Advanced Solid Tumor
Tango Therapeutics, Inc. 225
Large-scale testing (Phase 3)Looking for participantsNCT06300177
What this trial is testing

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Who this might be right for
Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 522
Testing effectiveness (Phase 2)UnknownNCT00722969
What this trial is testing

Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Universitair Ziekenhuis Brussel 48
Early research (Phase 1)UnknownNCT05360381
What this trial is testing

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsSquamous-cell Non-small Cell Lung Cancer
Shanghai Henlius Biotech 82
Testing effectiveness (Phase 2)Study completedNCT00061451
What this trial is testing

Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 48
Testing effectiveness (Phase 2)Looking for participantsNCT06799065
What this trial is testing

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+4 more
Accent Therapeutics 218
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Next Page